EAP for Deucrictibant Immediate-release
NCT07759141 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-08-12
Summary
This is an expanded access program (EAP) designed to allow access to deucrictibant immediate-release (IR) capsule for eligible participants with hereditary angioedema (HAE) in the United States (US) and US territories who lack satisfactory alternative treatment options for on-demand treatment of HAE attacks, as determined by their treating physician.
Conditions
Interventions
- DRUG
-
Deucrictibant IR
Deucrictibant IR capsule administered orally.
Sponsors & Collaborators
-
Pharvaris Netherlands B.V.
lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
NCT05047185 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
NCT07046806 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
NCT01457430 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
NCT07009262 ·Status: COMPLETED
-
Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
NCT06415448 ·Status: AVAILABLE
-
Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults
NCT04583007 ·Status: NO_LONGER_AVAILABLE
-
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema
NCT00097695 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00225147 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
NCT03485911 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00261053 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
NCT00004694 ·Status: COMPLETED ·Phase: NA
-
Oral Berotralstat Expanded Access Program
NCT04428632 ·Status: APPROVED_FOR_MARKETING
-
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
NCT02247739 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
NCT01188564 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
NCT01984788 ·Status: COMPLETED ·Phase: PHASE2
-
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00292981 ·Status: COMPLETED ·Phase: PHASE3
-
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00262288 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
NCT00500656 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
NCT03888755 ·Status: COMPLETED ·Phase: PHASE3
-
A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland
NCT05147181 ·Status: COMPLETED
-
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
NCT06628713 ·Status: APPROVED_FOR_MARKETING
-
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
NCT00912093 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
NCT02741596 ·Status: COMPLETED ·Phase: PHASE3